HYPR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

5.01M

+115.64%

-0.080

-42.86%

3.40M

+59.1%

-0.090

-25%

3.70M

+37.24%

-0.090

-25%

Estimates Revision

The market is revising Downward the revenue expectations for Hyperfine, Inc. (HYPR) for FY2025, with the revenue forecasts being adjusted by -7.03% over the past three months. During the same period, the stock price has changed by -42.29%.

Revenue Estimates for FY2025

Revise Downward

-7.03%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+5.81%

In Past 3 Month

Stock Price

Go Down

-42.29%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast HYPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYPR is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

Lake Street

Buy

maintain

2025-08-14

Reason

Lake Street

Price Target

2025-08-14

maintain

Buy

Reason

Lake Street raised the firm's price target on Hyperfine to $2 from $1.50 and keeps a Buy rating on the shares after the company reported Q2 results and reiterated 2025 guidance for 10%-20% revenue growth. The firm believes a growth inflection supports multiple expansion, the analyst tells investors in a post-earnings note.

B. Riley

Yuan Zhi

Buy

maintain

2025-06-03

Reason

B. Riley

Yuan Zhi

Price Target

2025-06-03

maintain

Buy

Reason

B. Riley analyst Yuan Zhi reiterates a Buy rating on Hyperfine with a $1 price target after the company's premium Swoop received FDA 510k approval weeks ahead of schedule. The new next-generation MRI system includes a new scanner and Optive artificial intelligence software, producing the highest level of image quality and uniformity, the analyst tells investors in a research note. The firm says Hyperfine kept the hardware development confidential up until yesterday, so it is likely not on many investor radars. Riley points out the trading volume of Hyperfine on Monday was greater than 100M shares, more than the entire float. This trading abnormality could be related to trading algorithms catching the keyword "AI," the firm contends.

B. Riley

Buy

downgrade

2025-05-15

Reason

B. Riley

Price Target

2025-05-15

downgrade

Buy

Reason

B. Riley lowered the firm's price target on Hyperfine to $1 from $1.20 and keeps a Buy rating on the shares. The Q1 sales miss was driven by the loss of several orders at large academic institutions that were funded by research grants, which was a result of the tension between academic institutions and the current administration, the analyst tells investors in a research note. The firm awaits more clarity in the second half of 2025.

Lake Street

Frank Takkinen

Strong Buy

Initiates

$1.5

2025-03-24

Reason

Lake Street

Frank Takkinen

Price Target

$1.5

2025-03-24

Initiates

Strong Buy

Reason

Lake Street analyst Frank Takkinen initiated coverage of Hyperfine with a Buy rating and $1.50 price target. Hyperfine's ultra-low field MR imaging system, Swoop, provides diagnostic quality brain imaging at the bedside and the company is also collecting clinical data to support use in new indications and settings of care to expand the total addressable market, the analyst tells investors. The firm believes "a robust foundation has been built," with new indications expected to drive growth and margin expansion, the analyst added.

B. Riley Securities

Yuan Zhi

Strong Buy

Maintains

$1.5 → $1.2

2025-03-20

Reason

B. Riley Securities

Yuan Zhi

Price Target

$1.5 → $1.2

2025-03-20

Maintains

Strong Buy

Reason

B. Riley analyst Yuan Zhi lowered the firm's price target on Hyperfine to $1.20 from $1.50 and keeps a Buy rating on the shares. The top-line miss in in Q4 was driven by extended timelines in legacy critical care business, and guidance for the first half of 2025 implies a continued slowdown, while 2025 guidance implies a sharp revenue increase in the second half of the year, the analyst tells investors in a research note. Uncertainty remains, and management will have more visibility in the coming months amid new sales reps and new opportunities, the firm adds.

Wells Fargo

Larry Biegelsen

Hold

Maintains

$1.1 → $1.29

2025-03-18

Reason

Wells Fargo

Larry Biegelsen

Price Target

$1.1 → $1.29

2025-03-18

Maintains

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Hyperfine Inc (HYPR.O) is -2.77, compared to its 5-year average forward P/E of -1.82. For a more detailed relative valuation and DCF analysis to assess Hyperfine Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.82

Current PE

-2.77

Overvalued PE

-0.59

Undervalued PE

-3.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.62

Current EV/EBITDA

-2.44

Overvalued EV/EBITDA

1.18

Undervalued EV/EBITDA

-2.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

7.02

Current PS

5.64

Overvalued PS

15.63

Undervalued PS

-1.59

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

HYPR News & Events

Events Timeline

No data

News

3.5

2025-12-17Businesswire

Hyperfine Receives Regulatory Approval for Swoop® Portable MRI System in India, Addressing Critical Brain Imaging Needs

3.5

2025-12-15Newsfilter

Hyperfine Receives FDA Clearance for New DWI Software Enhancing Stroke Diagnosis

3.5

2025-12-15Businesswire

Hyperfine Receives FDA Clearance for New DWI Software Enhancing Brain MRI Imaging Quality

People Also Watch

Frequently Asked Questions

What is Hyperfine Inc (HYPR) stock price today?

The current price of HYPR is 1.01 USD — it has increased 1.92 % in the last trading day.

What is Hyperfine Inc (HYPR)'s business?

Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.

What is the price predicton of HYPR Stock?

What is Hyperfine Inc (HYPR)'s revenue for the last quarter?

Hyperfine Inc revenue for the last quarter amounts to 3.44M USD, decreased -5.65 % YoY.

What is Hyperfine Inc (HYPR)'s earnings per share (EPS) for the last quarter?

Hyperfine Inc. EPS for the last quarter amounts to -0.14 USD, decreased -0.00 % YoY.

What changes have occurred in the market's expectations for Hyperfine Inc (HYPR)'s fundamentals?

How many employees does Hyperfine Inc (HYPR). have?

Hyperfine Inc (HYPR) has 111 emplpoyees as of January 10 2026.

What is Hyperfine Inc (HYPR) market cap?

Today HYPR has the market capitalization of 98.14M USD.